A GATE simulation study for dosimetry in cancer cell and micrometastasis from the 225Ac decay chain

EJNMMI Physics

Original Research

Cassandra Miller¹  Arman Rahmim²  Carlos Uribe³  Helena Koniar⁴  Paul Schaffer⁵ 

[1] Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada;Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada;Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada;Department of Integrative Oncology, BC Cancer Research Institute, Vancouver, BC, Canada;Department of Radiology, University of British Columbia, Vancouver, BC, Canada;Department of Radiology, University of British Columbia, Vancouver, BC, Canada;Functional Imaging, BC Cancer, Vancouver, BC, Canada;Life Sciences Division, TRIUMF, Vancouver, BC, Canada;Department of Physics and Astronomy, University of British Columbia, Vancouver, BC, Canada;Life Sciences Division, TRIUMF, Vancouver, BC, Canada;Department of Radiology, University of British Columbia, Vancouver, BC, Canada;Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada;

关键词: Actinium-225;    Radiopharmaceutical therapy;    Microdosimetry;    S;    Monte Carlo simulations;   

DOI  :  10.1186/s40658-023-00564-5

 received in 2022-12-27, accepted in 2023-07-24,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundRadiopharmaceutical therapy (RPT) with alpha-emitting radionuclides has shown great promise in treating metastatic cancers. The successive emission of four alpha particles in the 225Ac decay chain leads to highly targeted and effective cancer cell death. Quantifying cellular dosimetry for 225Ac RPT is essential for predicting cell survival and therapeutic success. However, the leading assumption that all 225Ac progeny remain localized at their target sites likely overestimates the absorbed dose to cancer cells. To address limitations in existing semi-analytic approaches, this work evaluates S-values for 225Ac’s progeny radionuclides with GATE Monte Carlo simulations.MethodsThe cellular geometries considered were an individual cell (10 µm diameter with a nucleus of 8 µm diameter) and a cluster of cells (micrometastasis) with radionuclides localized in four subcellular regions: cell membrane, cytoplasm, nucleus, or whole cell. The absorbed dose to the cell nucleus was scored, and self- and cross-dose S-values were derived. We also evaluated the total absorbed dose with various degrees of radiopharmaceutical internalization and retention of the progeny radionuclides 221Fr (t1/2 = 4.80 m) and 213Bi (t1/2 = 45.6 m).ResultsFor the cumulative 225Ac decay chain, our self- and cross-dose nuclear S-values were both in good agreement with S-values published by MIRDcell, with per cent differences ranging from − 2.7 to − 8.7% for the various radionuclide source locations. Source location had greater effects on self-dose S-values than the intercellular cross-dose S-values. Cumulative 225Ac decay chain self-dose S-values increased from 0.167 to 0.364 GyBq−1 s−1 with radionuclide internalization from the cell surface into the cell. When progeny migration from the target site was modelled, the cumulative self-dose S-values to the cell nucleus decreased by up to 71% and 21% for 221Fr and 213Bi retention, respectively.ConclusionsOur GATE Monte Carlo simulations resulted in cellular S-values in agreement with existing MIRD S-values for the alpha-emitting radionuclides in the 225Ac decay chain. To obtain accurate absorbed dose estimates in 225Ac studies, accurate understanding of daughter migration is critical for optimized injected activities. Future work will investigate other novel preclinical alpha-emitting radionuclides to evaluate therapeutic potency and explore realistic cellular geometries corresponding to targeted cancer cell lines.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 4

13690_2023_1147_Article_IEq20.gif

13690_2023_1147_Article_IEq19.gif

13690_2023_1147_Article_IEq18.gif

13690_2023_1147_Article_IEq7.gif

13690_2023_1147_Article_IEq6.gif

Fig. 2

13690_2023_1147_Article_IEq4.gif

13690_2023_1147_Article_IEq3.gif

13690_2023_1147_Article_IEq1.gif

Fig. 3

Fig. 1.

Fig. 3

Fig. 2

Fig. 2

Fig. 2